media – Page 610 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Source: Sandoz
637
January 23, 2018

Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.

Source: Endpts
579
January 23, 2018

Bavencio cancer inhibitor Market Views

Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...

Source: Pharmatimes
583
January 23, 2018

Avastin Mvasi New Approvals Roche

GSK, Pfizer lead in new global Twitter pharma influencer ranking

Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health. The U.K.-based healthcare marketing agency evaluated 22 pharma companies on authority, reach, activity, engagement and influence to rate the most and least adept when it comes to Twitter.

Source: fiercepharma
640
January 23, 2018

global pharma influencers GSK Pfizer

IoT devices vulnerable to Spectre and Meltdown exploitation

Healthcare organizations should use risk management processes to ensure the security of health information and protect against the vulnerabilities stemming from the Spectre and Meltdown threats.

Source: Healthcare IT News
539
January 23, 2018

healthcare technology Internet of Things Market Views medical device

Diagnostic Products of the Future

Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.

Source: MDDI Online
793
January 23, 2018

diagnostics healthcare technologies and innovations medical device Researches

Digital currency-based fitness app Sweatcoin lands $5.7M in funding

Earning a little extra toward workout products and fitness classes could be as easy as tracking the steps you take outside. London-based Sweatcoin, a company which “pays” users a digital currency based on their daily steps, has just landed $5.7 million in a funding round led by Goodwater Capital with participation from Seedcamp, Greylock Partners, Rubylight, SmartHub, and several angel investors.

Source: Mobile Health News
669
January 23, 2018

blockchain Company Insight digital health mHealth

Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.

Source: finance.yahoo
948
January 22, 2018

antibody Company Insight immunomodulation

Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.

Source: Prnewswire
786
January 22, 2018

biopharmaceutical EP4 antagonist Market Views

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to advance public health measures.

Source: medicalxpress
690
January 22, 2018

smallpox synthetic DNA synthetic virus vaccine

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Merck KGaA taps UK cancer research organizations to feed pipeline

Biosimilar Avastin wins EU approval

GSK, Pfizer lead in new global Twitter pharma influencer ranking

IoT devices vulnerable to Spectre and Meltdown exploitation

Diagnostic Products of the Future

Digital currency-based fitness app Sweatcoin lands $5.7M in funding

Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us